Benzinga · Aug 28, 2026
BioAtla To Be Delisted From Nasdaq Following Listing Council Decision; Trading Suspension Effective August 31, With Shares Expected To Transition To OTC Markets
-SEC Filing
NASDAQ · BCAB
BioAtla, Inc.
Healthcare · Biotechnology
$1.74
Up+$0.42 (+31.44%)
Updated Oct 6, 2026, 8:14 PM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 46.1M
- P/E ratio
- -0.94
- Dividend yield
- 0.00%
- 52-week range
- $0.15 – $8.20
- Volume
- 1.03M
- Avg. volume
- 1.41M
Price performance · BCAB
BCAB price history
1M range · 0 trading sessions · Daily adjusted prices
BCAB does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest BCAB news
The latest Smart Investors Daily articles mentioning BCAB.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BCAB research
Overview
Company profile and research snapshot.
Company profile
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $5.00
- Implied upside
- —
- Analysts
- 7
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2025 | JMP Securities | Market Perform | — |
| Mar 31, 2025 | Citizens Capital Markets | Market Outperform | — |
| Mar 31, 2025 | HC Wainwright & Co. | Neutral | — |
| Nov 13, 2024 | HC Wainwright & Co. | Neutral | — |
| Sep 16, 2024 | JMP Securities | Market Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 2, 2026
BioAtla Initiates Exploration Of Strategic Initiatives Including Workforce Reduction Of ~70%; Appoints Chris Vasquez CFO, Succeeding Richard Waldron
SEC.
Benzinga · Mar 2, 2026
BioAtla Board Initiates Formal Process To Explore And Evaluate Strategic Options To Monetize Assets
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, announced that the
Benzinga · Jan 27, 2026
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
